These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 29173045)

  • 1. Multiplicity issues in exploratory subgroup analysis.
    Lipkovich I; Dmitrienko A; Muysers C; Ratitch B
    J Biopharm Stat; 2018; 28(1):63-81. PubMed ID: 29173045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tutorial in biostatistics: data-driven subgroup identification and analysis in clinical trials.
    Lipkovich I; Dmitrienko A; B R
    Stat Med; 2017 Jan; 36(1):136-196. PubMed ID: 27488683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiplicity considerations in subgroup analysis.
    Dmitrienko A; Millen B; Lipkovich I
    Stat Med; 2017 Dec; 36(28):4446-4454. PubMed ID: 28762525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Penalty-based approaches to evaluating multiplicity adjustments in clinical trials: Advanced multiplicity problems.
    Paux G; Dmitrienko A
    J Biopharm Stat; 2018; 28(1):169-188. PubMed ID: 29125802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of treatment effect in two-stage confirmatory oncology trials of personalized medicines.
    Li W; Chen C; Li X; Beckman RA
    Stat Med; 2017 May; 36(12):1843-1861. PubMed ID: 28303586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addressing multiplicity issues of a composite endpoint and its components in clinical trials.
    Huque MF; Alosh M; Bhore R
    J Biopharm Stat; 2011 Jul; 21(4):610-34. PubMed ID: 21516560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An enhanced mixture method for constructing gatekeeping procedures in clinical trials.
    Kordzakhia G; Brechenmacher T; Ishida E; Dmitrienko A; Zheng WW; Li DF
    J Biopharm Stat; 2018; 28(1):113-128. PubMed ID: 29239689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Key multiplicity issues in clinical drug development.
    Dmitrienko A; D'Agostino RB; Huque MF
    Stat Med; 2013 Mar; 32(7):1079-111. PubMed ID: 23044723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Data-Driven Subgroup Identification in Confirmatory Clinical Trials.
    Bunouf P; Groc M; Dmitrienko A; Lipkovich I
    Ther Innov Regul Sci; 2022 Jan; 56(1):65-75. PubMed ID: 34327673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarker threshold adaptive designs for survival endpoints.
    Diao G; Dong J; Zeng D; Ke C; Rong A; Ibrahim JG
    J Biopharm Stat; 2018; 28(6):1038-1054. PubMed ID: 29436940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiplicity in confirmatory clinical trials: a case study with discussion from a JSM panel.
    Wang SJ; Bretz F; Dmitrienko A; Hsu J; Hung HM; Koch G; Maurer W; Offen W; O'Neill R
    Stat Med; 2015 Nov; 34(26):3461-80. PubMed ID: 26112381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Penalty-based approaches to evaluating multiplicity adjustments in clinical trials: Traditional multiplicity problems.
    Paux G; Dmitrienko A
    J Biopharm Stat; 2018; 28(1):146-168. PubMed ID: 29172961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. General guidance on exploratory and confirmatory subgroup analysis in late-stage clinical trials.
    Dmitrienko A; Muysers C; Fritsch A; Lipkovich I
    J Biopharm Stat; 2016; 26(1):71-98. PubMed ID: 26366479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An introduction to multiplicity issues in clinical trials: the what, why, when and how.
    Li G; Taljaard M; Van den Heuvel ER; Levine MA; Cook DJ; Wells GA; Devereaux PJ; Thabane L
    Int J Epidemiol; 2017 Apr; 46(2):746-755. PubMed ID: 28025257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On Enrichment Strategies for Biomarker Stratified Clinical Trials.
    Wang X; Zhou J; Wang T; George SL
    J Biopharm Stat; 2018; 28(2):292-308. PubMed ID: 28933670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simple subgroup approximations to optimal treatment regimes from randomized clinical trial data.
    Foster JC; Taylor JM; Kaciroti N; Nan B
    Biostatistics; 2015 Apr; 16(2):368-82. PubMed ID: 25398774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies for identifying predictive biomarkers and subgroups with enhanced treatment effect in clinical trials using SIDES.
    Lipkovich I; Dmitrienko A
    J Biopharm Stat; 2014; 24(1):130-53. PubMed ID: 24392982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bayesian models for subgroup analysis in clinical trials.
    Jones HE; Ohlssen DI; Neuenschwander B; Racine A; Branson M
    Clin Trials; 2011 Apr; 8(2):129-43. PubMed ID: 21282293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Data Monitoring Committees and early stopping guidelines: the Southwest Oncology Group experience.
    Crowley J; Green S; Liu PY; Wolf M
    Stat Med; 1994 Jul 15-30; 13(13-14):1391-9. PubMed ID: 7973218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SOP 09: Statistical design and analysis.
    Onkologie; 2003 Oct; 26 Suppl 6():43-7. PubMed ID: 23570186
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.